TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck: FDA reviewing tablet to eliminate allergy

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

By The Associated Press
Thursday, March 28, 2013, 12:01 a.m.
 

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that reduces symptoms over time, rather than just temporarily relieving the sneezing and itching.

The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the United States to a long series of uncomfortable allergy shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction. Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season.

for three years.

The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Real estate union: Howard Hanna buys Langholz Wilson Ellis
  2. EPA says it won’t reguluate coal ash as hazardous waste
  3. Asked about Cuban cigars’ availability, retailers point to trade embargo
  4. Treasury turns profit as it exits GM bailout
  5. ExOne Co. moves solidify authority under CEO
  6. Americans support strict rules for drones in poll
  7. Upscale Verano takes part in Buick’s success
  8. CR-V popular, fuel-efficient
  9. Pennsylvania jobless rate drops to 5.1 percent
  10. Some in Western Pa. affected by Staples data breach
  11. Western Pa. utility workers OK contract with FirstEnergy
Subscribe today! Click here for our subscription offers.